Edition:
United Kingdom

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
15 Dec 2017
Change (% chg)

$0.08 (+2.86%)
Prev Close
$2.62
Open
$2.60
Day's High
$2.85
Day's Low
$2.53
Volume
171,239
Avg. Vol
70,289
52-wk High
$3.60
52-wk Low
$1.58

Chart for

About

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $166.43
Shares Outstanding(Mil.): 55.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

14 Dec 2017

BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary

* BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL

27 Nov 2017

BRIEF-BioDelivery Sciences reports Q3 loss per share $0.21

* BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

12 Oct 2017

BRIEF-BioDelivery Sciences CEO Mark Sirgo to retire

* BioDelivery Sciences president and chief executive officer Mark Sirgo to retire at year-end while continuing as vice chairman

23 Aug 2017

BRIEF-BioDelivery Sciences reports Q2 loss per share $0.27

* BioDelivery Sciences reports second quarter 2017 financial results and provides corporate update

09 Aug 2017

BRIEF-Biodelivery Sciences signs agreement with Purdue Pharma

* Biodelivery Sciences signs exclusive agreement with Purdue Pharma (Canada) for the licensing and distribution rights of Belbuca in Canada

12 Jul 2017

BRIEF-Biodelivery Sciences announces Health Canada approval of Belbuca

* Biodelivery Sciences announces Health Canada approval of Belbuca®

23 Jun 2017

BRIEF-BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca, Bunavail

* BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca® and Bunavail® through 2020

21 Jun 2017

Earnings vs. Estimates